NCT03626415View on ClinicalTrials.gov

A Hepatic Impairment Study for PF-04965842.

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

October 1, 2018

Primary Completion Date

April 30, 2019

Study Completion Date

April 30, 2019

Conditions
Hepatic Impairment
Interventions
DRUG

PF-04965842

PF 04965842 is an orally bioavailable small molecule that selectively inhibits JAK1.

Trial Locations (2)

32809

Orlando Clinical Research Center, Orlando

55114

Prism Clinical Research, LLC, Saint Paul

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT03626415 - A Hepatic Impairment Study for PF-04965842. | Biotech Hunter | Biotech Hunter